{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:15:17Z","timestamp":1794003317600,"version":"4.8.0"},"reference-count":93,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastric cancer carries a poor prognosis and is a leading cause of cancer-related mortality worldwide. Patients with gastric cancer who develop peritoneal metastases have an even more dismal prognosis, with median survival time measured in months. Since studies have demonstrated that systemic chemotherapy has poor penetration into the peritoneum, multimodal treatment with intraperitoneal chemotherapy has been proposed for the treatment of peritoneal metastases and has become the foundation for newer therapeutic techniques and clinical trials. These include heated intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS), which involves the application of heated chemotherapy into the abdomen with or without tumor debulking surgery; normothermic intraperitoneal chemotherapy (NIPEC), in which non-heated chemotherapy can be delivered into the abdomen via a peritoneal port allowing for repeat dosing; and pressurized intraperitoneal aerosolized chemotherapy (PIPAC), a newer technique of pressurized and aerosolized chemotherapy delivered into the abdomen during laparoscopy. Early results with intraperitoneal chemotherapy have shown promise in increasing disease-free and overall survival in select patients. Additionally, there may be a palliative effect of these regional therapies. In this review, we explore and summarize these different intraperitoneal chemotherapy treatment regimens for gastric cancer with peritoneal metastases.<\/jats:p>","DOI":"10.3390\/cancers14030570","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T20:32:52Z","timestamp":1642969972000},"page":"570","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases"],"prefix":"10.3390","volume":"14","author":[{"given":"Beatrice J.","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Surgery, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byrne","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"ref_1","unstructured":"(2021, August 21). Estimated Number of Deaths Worldwide, Both Sexes, All Ages Cancer Today. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/7-Stomach-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1245\/s10434-021-09927-7","article-title":"The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS\/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum","volume":"28","author":"Dineen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","article-title":"Recent Advances in Intra-peritoneal Chemotherapy for Gastric Cancer","volume":"20","author":"Chia","year":"2020","journal-title":"J. Gastric Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Gastric Cancer (2021, August 21). Version 4.2021-8.2021, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jjco\/hym131","article-title":"A Phase II Study of Oxaliplatin with Low-dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFOX-4) for Gastric Cancer Patients with Malignant Ascites","volume":"37","author":"Oh","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jjco\/hyt114","article-title":"Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)","volume":"43","author":"Shirao","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jjco\/hyh063","article-title":"Phase II Study of Sequential Methotrexate and 5-Fluorouracil Chemotherapy against Peritoneally Disseminated Gastric Cancer with Malignant Ascites: A Report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial","volume":"34","author":"Yamao","year":"2004","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III Study of Docetaxel and Cisplatin plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group","volume":"24","author":"Moiseyenko","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_12","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.21037\/jgo-2020-04","article-title":"Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: An overview of common therapeutic regimens","volume":"12","author":"Brandl","year":"2021","journal-title":"J. Gastrointest Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","article-title":"A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy","volume":"2","author":"Yan","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_15","first-page":"1","article-title":"Theoretical and experimental bases of intraperitoneal chemotherapy","volume":"12","author":"Dedrick","year":"1985","journal-title":"Semin. Oncol."},{"key":"ref_16","first-page":"256","article-title":"Clinical Delivery System for Intraperitoneal Hyperthermic Chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_17","first-page":"253","article-title":"Hyperthermic Peritoneal Perfusion System in Canines","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U","article-title":"Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C","volume":"61","author":"Koga","year":"1988","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal Hyperthermic Perfusion Combined with Surgery Effiective for Gastric Cancer Patients with Peritoneal Seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jso.10255","article-title":"Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion","volume":"83","author":"Deraco","year":"2003","journal-title":"J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.suc.2020.02.009","article-title":"Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy","volume":"100","author":"Pletcher","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","article-title":"Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS\u00ae) Society Recommendations\u2014Part I: Preoperative and intraoperative management","volume":"46","author":"Kusamura","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ejso.2020.08.006","article-title":"Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS\u00ae) Society Recommendations\u2014Part II: Postoperative management and special considerations","volume":"46","author":"Kusamura","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jso.23633","article-title":"Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial: Gastric Cancer Multimodal Therapy","volume":"110","author":"Rudloff","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer with Peritoneal Metastasis: PHOENIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis: PTX IP for Peritoneal Carcinomatosis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.21873\/anticanres.12945","article-title":"Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial","volume":"38","author":"Shinkai","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1245\/s10434-006-9205-7","article-title":"Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer","volume":"14","author":"Cheong","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s10120-018-0817-y","article-title":"A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: Final results of the INPACT trial","volume":"21","author":"Takahashi","year":"2018","journal-title":"Gastric Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ejso.2010.09.006","article-title":"Surgical treatment for peritoneal carcinomatosis from gastric cancer","volume":"36","author":"Yonemura","year":"2010","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials","volume":"40","author":"Coccolini","year":"2014","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","article-title":"A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology","volume":"28","author":"Badgwell","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4251\/wjgo.v2.i1.36","article-title":"Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"2","author":"Baratti","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","article-title":"Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-0036-1584501","article-title":"Postoperative Complications: Looking Forward to a Safer Future","volume":"29","author":"Tevis","year":"2016","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamasurg.2019.0995","article-title":"Association between Use of Enhanced Recovery after Surgery Protocol and Postoperative Complications in Colorectal Surgery: The Postoperative Outcomes within Enhanced Recovery After Surgery Protocol (POWER) Study","volume":"154","author":"Aldecoa","year":"2019","journal-title":"JAMA Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12957-019-1593-9","article-title":"Postoperative complications and prognosis after radical gastrectomy for gastric cancer: A systematic review and meta-analysis of observational studies","volume":"17","author":"Wang","year":"2019","journal-title":"World. J. Surg. Onc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","article-title":"Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin","volume":"37","author":"Laplace","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1245\/s10434-021-10508-x","article-title":"Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study","volume":"29","author":"Kurreck","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ssu.10042","article-title":"Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer","volume":"21","author":"Sugarbaker","year":"2003","journal-title":"Semin. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: Rationale and technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"22","author":"Seshadri","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/etm.2014.1599","article-title":"Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer","volume":"7","author":"Cui","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sun, J., Song, Y., Wang, Z., Gao, P., Chen, X., Xu, Y., Liang, J., and Xu, H. (2012). Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-526"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer","volume":"34","author":"Facchiano","year":"2008","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients: Laparoscopic HIPEC Is a Safe and Effective","volume":"100","author":"Valle","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","article-title":"Laparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature","volume":"19","author":"Facchiano","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases","volume":"28","author":"Saito","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","article-title":"Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings","volume":"20","author":"Ishigami","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11605-016-3336-3","article-title":"Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?","volume":"21","author":"Chan","year":"2017","journal-title":"J. Gastrointest. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-013-3208-y","article-title":"Salvage Gastrectomy after Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites","volume":"21","author":"Kitayama","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jso.24476","article-title":"Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review: Adjuvant IP Chemotherapy for Gastric Cancer","volume":"115","author":"Feingold","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-001-0067-7","article-title":"Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial","volume":"25","author":"Yu","year":"2001","journal-title":"World J. Surg."},{"key":"ref_64","first-page":"100025","article-title":"Role of intraperitoneal chemotherapy in gastric cancer","volume":"4","author":"Parray","year":"2021","journal-title":"Surg. Pr. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_66","first-page":"29","article-title":"Surgical technology and pharmacology of hyperthermic perioperative chemotherapy","volume":"7","author":"Sugarbaker","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4251\/wjgo.v7.i11.285","article-title":"Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a novel approach for intraperitoneal drug delivery and the related device","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11605-017-3565-0","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video)","volume":"22","author":"Cazauran","year":"2017","journal-title":"J. Gastrointest. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11605-018-3916-5","article-title":"How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience after a Consecutive Series of 1200 Procedures","volume":"22","author":"Tempfer","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejso.2017.03.019","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy\u2014Practical aspects","volume":"43","author":"Grass","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"De Simone, M., Vaira, M., Argenziano, M., Berchialla, P., Pisacane, A., Cinquegrana, A., Cavalli, R., Borsano, A., and Robella, M. (2020). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050102"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20180127","DOI":"10.1515\/pp-2018-0127","article-title":"The role of Pressurized IntraPeritoneal Aerosol Chemotherapy in the management of gastric cancer: A systematic review","volume":"4","author":"Garg","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10637-018-0641-6","article-title":"Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: Comparison of an experimental duplex drug to standard drug regimens in vitro","volume":"37","author":"Weinreich","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: A phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study","volume":"18","author":"Gockel","year":"2018","journal-title":"J. Gastric Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: An open-label, Phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2020","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10585-019-09955-4","article-title":"Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: An overview","volume":"36","author":"Alberto","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"TPS4132","DOI":"10.1200\/jco.2015.33.15_suppl.tps4132","article-title":"Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC)","volume":"33","author":"Rau","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Glehen, O., Passot, G., Villeneuve, D., Bin-Dorel, S., Boschetti, G., Piaton, E., and Garofalo, A. (2014). GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-183"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Koemans, W.J., van der Kaaij, R.T., Boot, H., Buffart, T., Veenhof, A.A.F.A., Hartemink, K.J., Grootscholten, C., Snaebjornsson, P., Retel, V.P., and van Tinteren, H. (2019). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5640-2"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-020-6701-2","article-title":"Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): Dragon II trial","volume":"20","author":"Beeharry","year":"2020","journal-title":"BMC Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: A randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"20180108","DOI":"10.1515\/pp-2018-0108","article-title":"Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy\u2014PIPAC-OPC2","volume":"3","author":"Graversen","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_92","unstructured":"(2021, August 27). PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients with Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04329494."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1245\/s10434-021-10505-0","article-title":"PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial","volume":"29","author":"Raoof","year":"2021","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/570\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:06:12Z","timestamp":1760133972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":93,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030570"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030570","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]}}}